Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682647 | 0.93 | ALDH1A1 (0.47) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT | |
| SCHEMBL6682842 | 0.92 | ALDH1A1 (0.49) | ALDH1A1MAPK1DRD2MAPTPOLB | |
| SCHEMBL6670427 | 0.92 | ALDH1A1 (0.49) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT | |
| SCHEMBL6680610 | 0.91 | DRD2 (0.45) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT | |
| SCHEMBL6664679 | 0.89 | SMN1; SMN2 (0.51) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT | |
| SCHEMBL6686372 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT | |
| SCHEMBL6664648 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPK1DRD2MAPTPOLB | |
| SCHEMBL6678354 | 0.86 | DRD2 (0.54) | ALDH1A1MAPK1DRD2MAPTPOLB | |
| SCHEMBL6664863 | 0.85 | DRD2 (0.46) | ALDH1A1MAPK1DRD2MAPTPOLB | |
| SCHEMBL6668774 | 0.84 | DRD2 (0.45) | ALDH1A1MAPK1DRD2SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | ALDH1A1 1202/4885MAPK1 857/4885DRD2 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.